New high-dose amoxicillin with clavulanate in therapy of acute respiratory and ENT infections in children

A significant growth of bacterial resistance to antimicrobial agents has been reported globally over the past decades. Pneumococcus and Haemophilus influenzae are the major respiratory and ENT pathogens among children in the Russian Federation. To date, the problem of rational and effective bacterial respiratory tract infections therapy remains unsettled. The emergence of the new high-dose amoxicillin with clavulanate provides additional opportunities for respiratory disease therapy in children with risk factors for drug-resistant pathogens.